Treatment for androgen-independet prostate cancer (AIPC)remains usatisfactory. The efficacy of Paclitaxel in androgen-independet prostate cancer and its cytotoxic synergy with anthracyclin drivatives led to determine the safety and efficacy of aa weekly schedule of Paclitaxel and Epidoxorubicin in AIPC
Phase II study of weekly combination of Paclitaxel and epidoxorubicin in hormone-refractory prostate cancer / D. Pantalone; B. Neri; C. Fulignati; M. Turrini; V. Della Melina; V. Di Cello; A. Dominici; A. Raugei. - In: EUROPEAN JOURNAL OF SURGICAL ONCOLOGY. - ISSN 0748-7983. - STAMPA. - 30:(2004), pp. 291.205-291.205.
Phase II study of weekly combination of Paclitaxel and epidoxorubicin in hormone-refractory prostate cancer
PANTALONE, DESIRE';NERI, BRUNO;
2004
Abstract
Treatment for androgen-independet prostate cancer (AIPC)remains usatisfactory. The efficacy of Paclitaxel in androgen-independet prostate cancer and its cytotoxic synergy with anthracyclin drivatives led to determine the safety and efficacy of aa weekly schedule of Paclitaxel and Epidoxorubicin in AIPC
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
